Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497899 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 279
- Enrollment target
NCT01497899 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 279 participants.
The verdict
NCT01497899, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 279 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
Interventions
- DRUG E/C/F/TAF
- DRUG E/C/F/TDF
- DRUG E/C/F/TDF Placebo
- DRUG E/C/F/TAF Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2011-12-28 |
| Est. Completion | 2016-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01497899
The ClinicalTrials.gov registry entry for NCT01497899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which E/C/F/TAF is the first listed.
NCT01497899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01497899 about?
NCT01497899 is a clinical study titled "Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults". The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, a...
What is the current status of trial NCT01497899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 279 participants. The study started on 2011-12-28. Estimated completion is 2016-08-22.
What interventions are being tested in trial NCT01497899?
The interventions under investigation include: E/C/F/TAF (DRUG), E/C/F/TDF (DRUG), E/C/F/TDF Placebo (DRUG), E/C/F/TAF Placebo (DRUG).
Who is sponsoring clinical trial NCT01497899?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.